Vir Biotechnology, Inc.
VIR
$9.26
-$0.22-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 504.86% | -89.92% | -60.52% | -94.62% | -40.24% |
| Total Other Revenue | 44.75% | -- | -- | -- | -- |
| Total Revenue | 417.78% | -89.92% | -60.52% | -94.62% | -26.29% |
| Cost of Revenue | -14.07% | -22.42% | -7.27% | 19.36% | -3.22% |
| Gross Profit | 73.07% | 21.59% | 5.67% | -171.79% | -1.10% |
| SG&A Expenses | -11.55% | -13.65% | -26.37% | -34.08% | -35.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.55% | -21.40% | -11.54% | 4.97% | -12.16% |
| Operating Income | 59.07% | 20.65% | 10.40% | -76.51% | 10.35% |
| Income Before Tax | 58.86% | 23.68% | 20.80% | -86.08% | 13.32% |
| Income Tax Expenses | -59.30% | -5.08% | 111.24% | -94.20% | 98.20% |
| Earnings from Continuing Operations | 58.96% | 23.66% | 19.82% | -85.31% | 9.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.96% | 23.66% | 19.82% | -85.31% | 9.82% |
| EBIT | 59.07% | 20.65% | 10.40% | -76.51% | 10.35% |
| EBITDA | 60.57% | 20.98% | 9.70% | -83.42% | 9.45% |
| EPS Basic | 59.67% | 24.91% | 21.11% | -82.36% | 11.27% |
| Normalized Basic EPS | 61.55% | 19.97% | 7.19% | -116.23% | 8.59% |
| EPS Diluted | 59.67% | 24.91% | 21.11% | -82.36% | 11.72% |
| Normalized Diluted EPS | 61.55% | 19.97% | 7.19% | -116.23% | 8.59% |
| Average Basic Shares Outstanding | 1.76% | 1.67% | 1.63% | 1.62% | 1.63% |
| Average Diluted Shares Outstanding | 1.76% | 1.67% | 1.63% | 1.62% | 1.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |